RU2574012C2 - Стабилизация fsh - Google Patents

Стабилизация fsh Download PDF

Info

Publication number
RU2574012C2
RU2574012C2 RU2012157154/15A RU2012157154A RU2574012C2 RU 2574012 C2 RU2574012 C2 RU 2574012C2 RU 2012157154/15 A RU2012157154/15 A RU 2012157154/15A RU 2012157154 A RU2012157154 A RU 2012157154A RU 2574012 C2 RU2574012 C2 RU 2574012C2
Authority
RU
Russia
Prior art keywords
rfsh
fsh
salt
salts
composition
Prior art date
Application number
RU2012157154/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2012157154A (ru
Inventor
Хелен Ульрика СЬЁГРЕН
Хейди Луис БАГГЕР
Original Assignee
Ферринг Б.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ферринг Б.В. filed Critical Ферринг Б.В.
Publication of RU2012157154A publication Critical patent/RU2012157154A/ru
Application granted granted Critical
Publication of RU2574012C2 publication Critical patent/RU2574012C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Fats And Perfumes (AREA)
RU2012157154/15A 2010-07-30 2011-07-28 Стабилизация fsh RU2574012C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10171428.5 2010-07-30
EP10171428A EP2417982A1 (en) 2010-07-30 2010-07-30 Stabilization of gonadotropins
PCT/EP2011/062986 WO2012013742A2 (en) 2010-07-30 2011-07-28 Stabilization of fsh

Publications (2)

Publication Number Publication Date
RU2012157154A RU2012157154A (ru) 2014-09-10
RU2574012C2 true RU2574012C2 (ru) 2016-01-27

Family

ID=43216624

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2012157154/15A RU2574012C2 (ru) 2010-07-30 2011-07-28 Стабилизация fsh

Country Status (27)

Country Link
US (3) US8993732B2 (enExample)
EP (3) EP2417982A1 (enExample)
JP (3) JP5860047B2 (enExample)
KR (2) KR101820115B1 (enExample)
CN (2) CN103052398B (enExample)
AR (1) AR082776A1 (enExample)
AU (1) AU2011284702C1 (enExample)
BR (1) BR112013002312B1 (enExample)
CA (1) CA2805864A1 (enExample)
DK (1) DK2598160T3 (enExample)
ES (1) ES2623634T3 (enExample)
HR (1) HRP20170386T1 (enExample)
HU (1) HUE033592T2 (enExample)
IL (2) IL223821A (enExample)
JO (1) JO3229B1 (enExample)
LT (1) LT2598160T (enExample)
MX (2) MX356951B (enExample)
NZ (2) NZ606366A (enExample)
PL (1) PL2598160T3 (enExample)
PT (1) PT2598160T (enExample)
RS (1) RS55772B1 (enExample)
RU (1) RU2574012C2 (enExample)
SA (1) SA114350786B1 (enExample)
SI (1) SI2598160T1 (enExample)
TW (1) TWI439283B (enExample)
WO (1) WO2012013742A2 (enExample)
ZA (1) ZA201209497B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI488640B (zh) 2008-04-16 2015-06-21 Ferring Int Ct Sa 藥學製劑
EP2417982A1 (en) * 2010-07-30 2012-02-15 Ferring B.V. Stabilization of gonadotropins
JO3092B1 (ar) 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
WO2015075743A1 (en) * 2013-11-12 2015-05-28 Cadila Healthcare Limited Formulation for gonadotropins
CN105727260A (zh) * 2016-02-03 2016-07-06 华侨大学 一种卵泡刺激素的长效制剂
GB201603280D0 (en) 2016-02-24 2016-04-13 Ferring Bv Stable liquid gonadotropin formulation
FR3083089A1 (fr) * 2018-06-29 2020-01-03 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
IL275148B2 (en) 2017-12-07 2025-02-01 Adocia An injectable solution with a pH of 7 comprising at least one basic insulin with a PI between 5.8 and 8.5 and a copolyamino acid bearing carboxylate charges and hydrophobic radicals.
KR20200106891A (ko) 2017-12-07 2020-09-15 아도시아 pI가 5.8 내지 8.5인 적어도 1종의 기저 인슐린, 및 카복실산염 전하 및 소수성 라디칼을 보유하는 코-폴리아미노산을 포함하는 pH 7의 주사용 용액
FR3084584B1 (fr) * 2018-08-03 2020-11-06 Adocia Solution injectable a ph 7 comprenant du glucagon humain et un compose amphiphile porteur de radicaux hydrophobes
FR3084586B1 (fr) * 2018-08-03 2020-11-06 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un compose amphiphile porteur de radicaux hydrophobes
JP7425459B2 (ja) * 2019-10-11 2024-01-31 株式会社シノテスト 安定化されたｈｍｇｂ１含有溶液

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2203086C2 (ru) * 1997-01-15 2003-04-27 Акцо Нобель Н.В. Жидкие композиции, содержащие гонадотропин
RU2208582C2 (ru) * 1996-05-29 2003-07-20 Биоксид Ой Средство для доставки, обеспечивающее непрерывное и/или регулируемое высвобождение биологически активных агентов
WO2009098318A1 (en) * 2008-02-08 2009-08-13 Biogenerix Ag Liquid formulation of fsh

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996029095A1 (en) 1995-03-21 1996-09-26 Applied Research Systems Ars Holding N.V. Hcg liquid formulations
US20030166525A1 (en) * 1998-07-23 2003-09-04 Hoffmann James Arthur FSH Formulation
PL346127A1 (en) * 1998-07-23 2002-01-28 Lilly Co Eli Fsh and fsh variant formulations, products and methods
UA89781C2 (uk) * 2004-04-07 2010-03-10 Арес Трейдінг С.А. Рідкий склад гормона росту
KR101105871B1 (ko) * 2005-09-27 2012-01-16 주식회사 엘지생명과학 인 난포자극호르몬의 안정한 용액 제형
TWI488640B (zh) 2008-04-16 2015-06-21 Ferring Int Ct Sa 藥學製劑
CN101614748A (zh) * 2008-06-25 2009-12-30 上海新波生物技术有限公司 促卵泡激素时间分辨免疫荧光分析法及试剂盒
JP5808323B2 (ja) * 2009-06-22 2015-11-10 アムジエン・インコーポレーテツド 化学的に制御されたレドックス状態を用いたタンパク質のリフォールディング
EP2533800B1 (en) * 2010-02-12 2016-07-20 Intas Pharmaceuticals Ltd. Liquid formulation of follicle stimulating hormone
EP2417982A1 (en) * 2010-07-30 2012-02-15 Ferring B.V. Stabilization of gonadotropins

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2208582C2 (ru) * 1996-05-29 2003-07-20 Биоксид Ой Средство для доставки, обеспечивающее непрерывное и/или регулируемое высвобождение биологически активных агентов
RU2203086C2 (ru) * 1997-01-15 2003-04-27 Акцо Нобель Н.В. Жидкие композиции, содержащие гонадотропин
WO2009098318A1 (en) * 2008-02-08 2009-08-13 Biogenerix Ag Liquid formulation of fsh

Also Published As

Publication number Publication date
IL223821A (en) 2017-01-31
HRP20170386T1 (hr) 2017-05-05
US20130210727A1 (en) 2013-08-15
TWI439283B (zh) 2014-06-01
CN105106939A (zh) 2015-12-02
CA2805864A1 (en) 2012-02-02
KR20180008916A (ko) 2018-01-24
AR082776A1 (es) 2013-01-09
KR101991756B1 (ko) 2019-06-21
BR112013002312B1 (pt) 2021-09-21
MX2013000681A (es) 2013-02-27
AU2011284702B2 (en) 2015-05-14
SA114350786B1 (ar) 2015-07-09
KR101820115B1 (ko) 2018-01-18
EP2598160B1 (en) 2017-02-22
RS55772B1 (sr) 2017-07-31
WO2012013742A2 (en) 2012-02-02
JP6522711B2 (ja) 2019-05-29
JO3229B1 (ar) 2018-03-08
KR20130143692A (ko) 2013-12-31
ES2623634T3 (es) 2017-07-11
TW201208694A (en) 2012-03-01
PL2598160T3 (pl) 2017-06-30
JP2016102127A (ja) 2016-06-02
US9463221B2 (en) 2016-10-11
JP5860047B2 (ja) 2016-02-16
EP2417982A1 (en) 2012-02-15
BR112013002312A2 (pt) 2018-03-20
US20150265681A1 (en) 2015-09-24
MX356951B (es) 2018-06-21
AU2011284702C1 (en) 2015-09-03
CN103052398A (zh) 2013-04-17
WO2012013742A3 (en) 2012-04-19
EP2598160A2 (en) 2013-06-05
MX341464B (es) 2016-08-22
AU2011284702A1 (en) 2013-02-07
IL249920A0 (en) 2017-03-30
NZ606366A (en) 2014-08-29
DK2598160T3 (en) 2017-03-27
PT2598160T (pt) 2017-03-30
SI2598160T1 (sl) 2017-07-31
US20170216405A1 (en) 2017-08-03
JP2013532677A (ja) 2013-08-19
CN103052398B (zh) 2015-09-16
LT2598160T (lt) 2017-04-10
HUE033592T2 (hu) 2017-12-28
NZ628962A (en) 2016-01-29
JP2018048188A (ja) 2018-03-29
ZA201209497B (en) 2013-08-28
EP3144010A1 (en) 2017-03-22
US8993732B2 (en) 2015-03-31
RU2012157154A (ru) 2014-09-10

Similar Documents

Publication Publication Date Title
RU2574012C2 (ru) Стабилизация fsh
EP2249869B1 (en) Liquid formulation of fsh
TWI755377B (zh) 穩定的液態促性腺激素調配物
JP4699991B2 (ja) 非イオン性界面活性剤を一緒に伴うｆｓｈ及びｌｈの液体医薬組成物
HK1184381B (en) Stabilization of fsh
HK1184381A (en) Stabilization of fsh
HK1149494B (en) Liquid formulation of fsh